Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
NCT Number: NCT05779111
In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.A retrospective study was conducted to explore the influence of 5 factors on PFS in patients with locally advanced cervical cancer receiving radiotherapy and chemotherapy.
Looking for future studies?
Notify Me18 year–70 year
Female
Observational
Chongqing, Chongqing Municipality, 400030, China
In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.5 factors included positive iliac lymph nodes, histological type, tumor size, positive pelvic lymph nodes on both sides, and maximum lymph node diameter greater than 1cm. Different factors give different scores.If the score is higher than 3, the probability of retroperitoneal lymph node metastasis in patients with locally advanced cervical cancer is significantly increased, and the prognosis of patients is affected. Patients with locally advanced cervix receiving radical radiotherapy were scored based on 5 factors.Patients with scores greater than or equal to 3 points were compared with patients with scores less than 3 points.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Locally advanced cervical cancer patients receiving radiotherapy
Time frame: 3 months
Whether there are differences in PFS between the two groups
Chongqing University Cancer Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03612791
Locally Advanced Cervical Cancer
Villejuif, Val de Marne, France
View Trial DetailsNCT03298893
Cervical Cancer, Female Urogenital Diseases
Paris, France
View Trial DetailsNCT06984289
Chemoradiotherapy, Female Urogenital Diseases
Roma, Italy
View Trial DetailsNCT03830866
Locally Advanced Cervical Cancer
Phoenix, Arizona, United States
View Trial Details